% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Werner:1048894,
      author       = {Werner, Jan-Michael and Mair, Maximilian J. and Wollring,
                      Michael M. and Barci, Enio and Stetter, Isabelle and Puhr,
                      Hannah C. and Tscherpel, Caroline and Stoffels, Gabriele and
                      Hainfellner, Johannes A. and Berghoff, Anna S. and
                      Sunder-Plassmann, Vincent and Widhalm, Georg and Eckert,
                      Franziska and Kasprian, Gregor and Nakuz, Thomas S. and
                      Beck, Alexander and Harter, Patrick N. and von Baumgarten,
                      Louisa and Thon, Niklas and Schönecker, Stephan and
                      Forbrig, Robert and Mottaghy, Felix M. and Lohmann, Philipp
                      and Fink, Gereon R. and Langen, Karl-Josef and Galldiks,
                      Norbert and Albert, Nathalie L. and Preusser, Matthias},
      title        = {{C}linical potential of [18{F}]{FET} {PET} in patients with
                      circumscribed astrocytic glioma},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {53},
      issn         = {1619-7070},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {FZJ-2025-04995},
      pages        = {2764–2776},
      year         = {2026},
      note         = {Funding Open access funding provided by Medical University
                      of Vienna. Funded by the research budget of the Medical
                      University of Vienna. Financial support by the Austrian
                      Federal Ministry for Digital and Economic Affairs, the
                      National Foundation for Research, Technologyand Development
                      and the Christian Doppler Research Association is gratefully
                      acknowledged. Supported by personal funding (J-M.W.) from
                      the German Cancer Aid (Deutsche Krebshilfe). M.J.M.
                      acknowledges personal funding from the European Society of
                      Medical Oncology(ESMO) through a Translational Research
                      Fellowship. This project was supported by Nuclear Medicine
                      and Neurooncology (NMN).Eur J Nucl Med Mol Imaging 2025 Nov
                      18. doi: 10.1007/s00259-025-07654-9. Online ahead of print.
                      Published online 18 Nov 2025},
      abstract     = {PurposeTo investigate the clinical potential of
                      O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) PET imaging in
                      the management of circumscribed astrocytic gliomas (CAG), a
                      rare glioma subtype with limited imaging data.MethodsWe
                      retrospectively identified adult CAG patients who underwent
                      [18F]FET PET imaging (i) before diagnosis, (ii) at suspected
                      relapse, or (iii) for response assessment at three
                      institutions. Maximum and mean tumor-to-brain ratios
                      (TBRmax, TBRmean) and metabolic tumor volumes were assessed
                      according to the PET RANO 1.0 criteria. Diagnostic
                      performance in differentiating treatment-related changes
                      from tumor relapse was evaluated using ROC analysis and
                      Fisher’s exact test.ResultsWe evaluated 79 [18F]FET PET
                      scans of 42 patients, including nine $(21\%)$ with
                      actionable molecular targets. Measurable [18F]FET uptake was
                      observed in $65\%$ of WHO grade 1 and $100\%$ of WHO grade 2
                      and 3 CAG. TBR values were significantly higher in WHO grade
                      2 and 3 CAG than in pilocytic astrocytomas (P < 0.01),
                      but showed no difference based on molecular target status
                      (P > 0.05). In 5 of 11 patients $(45\%),$ treatment
                      response assessment by PET RANO 1.0 differed from MRI.
                      Treatment-related changes were confirmed in 12 patients
                      $(43\%).$ In CAG WHO grades 2 or 3, the accuracy of [18F]FET
                      PET to identify treatment-related changes was $82\%$ using
                      single PET scans and $100\%$ using serial PET imaging
                      (P < 0.05).Conclusions[18F]FET PET can contribute to
                      clinical management of patients with CAG by detecting
                      measurable disease, differentiating treatment-related
                      changes from tumor progression, and showing potential in
                      treatment response assessment through longitudinal imaging.},
      cin          = {INM-4 / INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-3-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525) / 5252 - Brain Dysfunction
                      and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253 / G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1007/s00259-025-07654-9},
      url          = {https://juser.fz-juelich.de/record/1048894},
}